Global Monkeypox Vaccine Industry: Key Statistics and Insights in 2024-2032

Summary:

• The global monkeypox vaccine market size reached USD 86.6 Million in 2023.

• The market is expected to reach USD 421.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.85% during 2024-2032.

• North America leads the market, accounting for the largest monkeypox vaccine market share.

• Based on the type, the market has been divided into replication-competent and replication-deficient.

• Subcutaneous holds the largest share in the monkeypox vaccine industry.

• Hospital pharmacies remain a dominant segment in the market owing to their ability to manage large-scale vaccine storage and distribution.

• Hospitals represents the biggest end user segment.

• Growing concerns on health is a primary driver of the monkeypox vaccine market.
• Increasing investment in research and development, along with expanding public-private partnerships, are reshaping the monkeypox vaccine market.

Industry Trends and Drivers:

• Rising global health trends:

Global health authorities are prioritizing the development and distribution of monkeypox vaccines due to the rising incidence of cases across various regions. Governing agencies of several countries are responding by implementing vaccination campaigns and educating the public on the significance of immunization. Organizations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) are monitoring outbreaks, advocating for global preparedness, and recommending vaccination as a key prevention strategy. This focus on preventive measures is driving the demand for monkeypox vaccines, as public health officials are emphasizing early intervention. The rising public awareness about the transmission risk of the disease is increasing efforts to vaccinate high-risk populations and contain the spread, thereby simulating the market growth.

• Increasing investments in research and development:

Pharmaceutical companies are investing in research and development (R&D) activities to create effective monkeypox vaccines. The rising demand for the vaccine is encouraging organizations to accelerate their innovation by utilizing cutting-edge biotechnology to enhance vaccine efficacy and safety. Many firms are working on improving existing formulations, while some are developing new vaccines aimed at targeting emerging variants. Governing agencies of several countries are supporting these efforts through funding, regulatory streamlining, and public-private partnerships, ensuring that vaccines are developed and distributed quickly. The increasing investments is expanding the availability of vaccines and improving access for vulnerable populations, thereby addressing the rising need for immunization globally.

• Growing public-private partnerships:

Public and private entities are forming collaborative efforts to expedite the production and distribution of monkeypox vaccines. Governing agencies of several countries, healthcare organizations, and pharmaceutical companies are working together to ensure that vaccines reach vulnerable populations. These partnerships are focusing on optimizing supply chains, streamlining regulatory approvals, and coordinating global vaccination efforts. The collaboration between regulatory bodies and vaccine manufacturers is aiding in ensuring faster delivery without compromising safety or efficacy standards. Shared resources and expertise are allowing partners to enhance public health infrastructure and facilitate global access to vaccines. This coordinated approach is essential for controlling the spread of monkeypox and ensuring timely immunization programs in high-risk areas.

Request for a sample copy of this report: https://www.imarcgroup.com/monkeypox-vaccine-market/requestsample

Monkeypox Vaccine Market Report Segmentation:

Breakup By Type:

• Replication-competent
• Replication-deficient

On the basis of the type, the market has been bifurcated into replication-competent and replication-deficient.

Breakup By Route of Administration:

• Subcutaneous
• Percutaneous

Subcutaneous accounts for the majority of the market share due to its proven effectiveness in eliciting strong immune responses and ease of use for vaccines.

Breakup By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hospital pharmacies exhibit clear dominance in the market because they are key points of access for vaccines and are trusted by healthcare providers for administering specialized treatments.

Breakup By End User:

• Hospitals
• Clinics
• Others

Hospitals hold the biggest market share as they are primary healthcare centers for managing outbreaks and providing vaccinations to large populations.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position in the monkeypox vaccine market, which can be attributed to its advanced healthcare infrastructure and growing public awareness among people.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145